Inovio Pharmaceuticals (INO) Climbs On Preclinical Testing

Inovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals is having an incredible day in the market today after making a big early morning announcement. The company announced key results from the preclinical testing phase of a vaccine that is much needed in the medical industry. Today, we’ll talk about the preclinical testing results, how the market reacted to the news, and what we can expect to see from INO moving forward. So, let’s get right to it!

Trade smarter and make more money with Tradespoon!

INO Announces Preclinical Testing Results Of Zika Virus Vaccine

Zika Virus has been a big problem for quite some time now. It has even made its way into the United States. Recently, Inovio Pharmaceuticals announced that it was working on a vaccine for the virus. Today, the company announced results from the preclinical testing phase of the synthetic vaccine for the Zika virus. According to the preclinical results, the vaccine induced a robust and durable immune response and demonstrated the potential for a SynCon vaccine to prevent and treat infections fro the harmful pathogen. In a statement, Dr. J. Joseph Kim, INO President and CEO had the following to say:

Using our SynCon technology we rapidly generated a synthetic vaccine candidate that shows promise as a preventive and treatment. With robust antibody and killer T cell responses generated by our vaccine in mice, we will next test the vaccine in non-human primates and initiate clinical product manufacturing. We plan to initiate phase 1 human testing of our Zika vaccine before the end of 2016.”

How The Market Reacted To The News

As investors, we’ve learned that any time there’s positive news released with regard to a publicly traded company, we can expect to see a positive reaction in the market as a result. That’s exactly what we’re seeing from INO at the moment. After all, the Zika Virus vaccine is much needed in the medical community, and preliminary testing shows that the vaccine produced by INO is a strong candidate. Currently (10:09), INO is trading at $6.95 per share after a gain of $0.38 per share or 5.78% so far today.

What We Can Expect To See From INO Moving Forward

Moving forward, I have a relatively bullish opinion of what we can expect to see from Inovio Pharmaceuticals. The reality is that the company has proven its ability to create vaccines for some of the most pressing viruses out there. Now, INO is tackling the Zika Virus. This virus seems to be spreading quickly and has already made its way into the United States. This is a primary concern for consumers and medical professionals alike, and is generating a dire need for a Zika Virus vaccine. With the strong preclinical results, and the move to push this to human testing as quickly as possible, INO is likely going to be the company that produces the first, and most successful, vaccine for the virus. However, the Zika virus vaccine isn’t the only reason I’m bullish on Inovio Pharmaceuticals. Throughout its history, the company has proven that when it comes up with a plan, it follows through, leading to positive movement in revenue, earnings, and ultimately the value of the stock. All in all, I see no reason not to be bullish on INO!

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think INO is headed and why? Let us know your opinion in the comments below!

[Image Courtesy of Wikipedia]

Leave a Comment